Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Biden administration invests $3B to accelerate development of next-gen COVID-19 treatments

By Chris Newmarker | June 17, 2021

Election 2020 presidential election pharma Joe Biden

[Image courtesy of Biden for President]

President Joe Biden’s administration will spend $3 billion in American Rescue Plan money to accelerate the discovery, development and manufacturing of antiviral medicines against COVID-19, HHS announced today.

Not only will the Antiviral Program for Pandemics seek to boost the availability of medicines to prevent serious COVID-19 illness and save lives, but it will pursue sustainable discovery and development platforms that could produce antivirals against future viruses that threaten to spark pandemics.

The program is a collaboration within the U.S. Department of Health and Human Services (HHS) that includes the National Institutes of Health (NIH) and its National Institute of Allergy and Infectious Diseases (NIAID) — and the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR).

“New antivirals that prevent serious COVID-19 illness and death, especially oral drugs that could be taken at home early in the course of disease, would be powerful tools for battling the pandemic and saving lives,” Dr. Anthony Fauci, chief medical adviser to the president and NIAID director, said in a news release.

“Through multidisciplinary collaborations among leading scientists in academia and industry, this investment from the American Rescue Plan to create the Antiviral Program for Pandemics will help inspire medical innovation and build on the extraordinary success we have seen in developing the COVID-19 vaccines,” Fauci said.

Antivirals are an important enough piece of the U.S. strategy against COVID-19 that the federal government recently agreed to pay $1.2 billion to procure approximately 1.7 million courses of Merck‘s molnupiravir. Merck and Ridgeback Biotherapeutics collaborated on the development of molnupiravir.

Pfizer is also developing an oral antiviral targeting SARS-CoV-2 known as PF-07321332. The drug is currently the focus of a pair of Phase 1 studies.

 

 


Filed Under: Drug Delivery, RD
Tagged With: coronavirus, covid-19, HHS, Joe Biden, Merck, Pfizer
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Theravision_FDA Revised Carton
Johnson & Johnson is bringing the world’s first drug-eluting contact lens to market
midatech pharma janssen johnson & Johnson
J&J expands it long-acting injectables partnership with Midatech
Evonik launches new Eudratec tech to boost solubility of oral small molecules
PharmaJet Stratis
PharmaJet partner touts interim safety results for needle-free COVID-19 vaccine

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50